Our study not only expands the spectrum of SFTPA2 mutations and contributes to the genetic diagnosis and counseling of IPF patients but also provides a valuable, population‐specific SFTPA2 mutation that may contribute to further mechanistic and therapeutic research. This evidence concerns the gene SFTPA2 and idiopathic pulmonary fibrosis.